Quarterly Activities/Appendix 4C Cash Flow Report
| Stock | Neuroscientific Biopharmaceuticals Ltd (NSB.ASX) |
|---|---|
| Release Time | 30 Jan 2026, 8:27 a.m. |
| Price Sensitive | Yes |
Quarterly Activities/Appendix 4C Cash Flow Report
- StemSmart™ Special Access Program treating patients with Fistulising Crohn's Disease, with initial positive results
- Phase 2 clinical trial preparation progressing, informed by real-world data from Special Access Program
- Appointment of Clinical & Scientific Advisory Board to support ongoing StemSmart™ development
NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) has provided its Appendix 4C and Quarterly Activity Report for the period ended 31 December 2025. During the quarter, the company continued to advance the clinical and operational development of its proprietary StemSmart™ mesenchymal stem cell platform, with a focus on progressing the Special Access Program for patients with Fistulising Crohn's Disease. The program commenced, with initial results demonstrating a 'Clinical Response' following the reporting period. Major operations such as manufacturing technology transfer and clinical planning and regulatory work to support the planned Phase 2 clinical trial program have also progressed. The company announced the establishment of a new Clinical & Scientific Advisory Board to provide expert guidance as it advances the clinical development of the StemSmart™ platform. NeuroScientific's cash position was approximately $6.4 million as at 31 December 2025, providing funding to continue planned clinical development activities.
The company did not provide any high-importance, price-sensitive forward-looking financial metrics in the announcement.
The company did not provide any specific forward-looking outlook statements in the announcement.